US urged to launch Section 301 investigation into drug pricing

Summary

Trump is being urged to launch a Section 301 investigation into ‘unfair’ drug pricing, targeting the price disparity between the US and countries like Germany or Canada MSN. This follows a broader trend of using Section 301 to address trade imbalances and manufacturing reshoring money.udn.com+ 2. Recent policies already include 100% tariffs on certain imported medicines, with exemptions for companies that commit to domestic production and ‘Most Favored Nation’ (MFN) pricing Business Standard.

Impact Analysis

So, they’re basically admitting the previous tariff attempts hit a legal wall, and Section 301 is the new ‘legal’ hammer to force Big Pharma’s hand. This isn’t just about ‘unfair’ pricing in Canada or Germany MSN; it’s a massive reshoring play disguised as consumer protection. By threatening 100% tariffs on imports while offering ‘zero-tariff’ carrots for those who adopt MFN pricing and move R&D stateside , the administration is effectively trying to nationalize the pharmaceutical supply chain.

For the portfolio, this is a clear ‘divide and conquer’ for the sector. The real losers are the ones with heavy offshore manufacturing in China or India who can’t pivot in the 120-day window Business Standard. I’d be wary of generic manufacturers with thin margins—they simply can’t absorb a 100% tariff. The trade here is favoring domestic CDMOs and large-cap players who have the balance sheet to ‘buy’ their way into the MFN exemptions. Bottom line: the era of globalized, low-cost drug sourcing is officially under siege.